Clinical Trials Browser

Phase 2 × pemigatinib × 30 days × Clear all

NCT06728410 2026-03-09

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT07434843 2026-02-27

PEMIGIST

Phase 2 Not yet recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors